GDTC (CytoMed Therapeutics) Debt-to-Asset : 0.06 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GDTC CytoMed Therapeutics Ltd GDTC
27 GF Score
Price $0.92
! 2 Warning Signs
View Full Analysis

What is CytoMed Therapeutics Debt-to-Asset?

CytoMed Therapeutics GDTC -3.16% 27 Debt-to-Asset is 0.06 as of Dec. 2025. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

CytoMed Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.05 Mil. CytoMed Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.33 Mil. CytoMed Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was $6.19 Mil. CytoMed Therapeutics's debt to asset for the quarter that ended in Dec. 2025 was 0.06.

CytoMed Therapeutics  (NAS:GDTC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

CytoMed Therapeutics Debt-to-Asset Related Terms

CytoMed Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for CytoMed Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoMed Therapeutics Debt-to-Asset Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.54 0.81 0.04 0.05 0.06

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.05 0.06 0.06

GDTC vs GTBP, KALA, INAB: Debt-to-Asset Comparison

For the Biotechnology subindustry, CytoMed Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoMed Therapeutics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's Debt-to-Asset falls into.


GDTC
27GF Score
CytoMed Therapeutics Ltd GDTC
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoMed Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

CytoMed Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.046 + 0.327) / 6.187
=0.06

CytoMed Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.046 + 0.327) / 6.187
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.06 mean?
CytoMed Therapeutics (GDTC) has a Debt-to-Asset of 0.06 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on CytoMed Therapeutics and its competitors.
Is CytoMed Therapeutics' Debt-to-Asset too high?
CytoMed Therapeutics' current Debt-to-Asset is 0.06. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Debt-to-Asset compare to GTBP and KALA?
CytoMed Therapeutics' Debt-to-Asset of 0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current Debt-to-Asset is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current Debt-to-Asset of 0.06. The current Debt-to-Asset is 0.06. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current Debt-to-Asset is 0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoMed Therapeutics Business Description

Other Exchanges F98:Germany
Address 1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score

Get the complete analysis for GDTC

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.92
Price